These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 18245462)

  • 41. Urinary Biomarkers for Prostate Cancer.
    Tosoian JJ; Ross AE; Sokoll LJ; Partin AW; Pavlovich CP
    Urol Clin North Am; 2016 Feb; 43(1):17-38. PubMed ID: 26614026
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Urine markers in monitoring for prostate cancer.
    Jamaspishvili T; Kral M; Khomeriki I; Student V; Kolar Z; Bouchal J
    Prostate Cancer Prostatic Dis; 2010 Mar; 13(1):12-9. PubMed ID: 19652665
    [TBL] [Abstract][Full Text] [Related]  

  • 43. PCA3 sensitivity and specificity for prostate cancer detection in patients with abnormal PSA and/or suspicious digital rectal examination. First Latin American experience.
    Ramos CG; Valdevenito R; Vergara I; Anabalon P; Sanchez C; Fulla J
    Urol Oncol; 2013 Nov; 31(8):1522-6. PubMed ID: 22687565
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Urinary Biomarkers for Prostate Cancer.
    Giunchi F; Ciccarese C; Montironi R; Scarpelli M; Lopez-Beltran A; Cheng L; Moch H; Massari F; Fiorentino M
    Curr Drug Metab; 2017 Oct; 18(8):723-726. PubMed ID: 28524004
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparative analysis of prostate cancer specific biomarkers PCA3 and ERG in whole urine, urinary sediments and exosomes.
    Hendriks RJ; Dijkstra S; Jannink SA; Steffens MG; van Oort IM; Mulders PF; Schalken JA
    Clin Chem Lab Med; 2016 Mar; 54(3):483-92. PubMed ID: 26630694
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Perspectives of improvement of the diagnosis of prostate cancer based on analysis of PCA3 gene expression].
    Toropovsky AN; Nikitin AG; Pavlova ON; Viktorov DA
    Urologiia; 2019 Jun; (2):82-86. PubMed ID: 31162907
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of urinary prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer.
    Martínez-Piñeiro L; Schalken JA; Cabri P; Maisonobe P; de la Taille A;
    BJU Int; 2014 Oct; 114(4):608-16. PubMed ID: 24806330
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prostate cancer gene 3 (PCA3) is of additional predictive value in patients with PI-RADS grade III (intermediate) lesions in the MR-guided re-biopsy setting for prostate cancer.
    Kaufmann S; Bedke J; Gatidis S; Hennenlotter J; Kramer U; Notohamiprodjo M; Nikolaou K; Stenzl A; Kruck S
    World J Urol; 2016 Apr; 34(4):509-15. PubMed ID: 26267808
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Expression of PCA3 and PSA genes as a biomarker for differential diagnosis of nodular hyperplasia and prostate cancer.
    Coelho FF; Guimarães FL; Cabral WL; Salles PG; Mateo EC; Nogueira e Nogueira LM; Fonseca CE; Gomes KB
    Genet Mol Res; 2015 Oct; 14(4):13519-31. PubMed ID: 26535666
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Progensa™ PCA3 test for prostate cancer.
    Durand X; Moutereau S; Xylinas E; de la Taille A
    Expert Rev Mol Diagn; 2011 Mar; 11(2):137-44. PubMed ID: 21405964
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical utility of a novel urine-based gene fusion TTTY15-USP9Y in predicting prostate biopsy outcome.
    Zhu Y; Ren S; Jing T; Cai X; Liu Y; Wang F; Zhang W; Shi X; Chen R; Shen J; Lu J; Xu C; Wang H; Wang H; Wang Y; Liu B; Li Y; Fang Z; Guo F; Qiao M; Shen D; Lu X; Gao X; Hou J; Sun Y
    Urol Oncol; 2015 Sep; 33(9):384.e9-20. PubMed ID: 26008593
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Rational basis for the combination of PCA3 and TMPRSS2:ERG gene fusion for prostate cancer diagnosis.
    Robert G; Jannink S; Smit F; Aalders T; Hessels D; Cremers R; Mulders PF; Schalken JA
    Prostate; 2013 Jan; 73(2):113-20. PubMed ID: 22674214
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Multiparametric magnetic resonance imaging of the prostate can improve the predictive value of the urinary prostate cancer antigen 3 test in patients with elevated prostate-specific antigen levels and a previous negative biopsy.
    Sciarra A; Panebianco V; Cattarino S; Busetto GM; De Berardinis E; Ciccariello M; Gentile V; Salciccia S
    BJU Int; 2012 Dec; 110(11):1661-5. PubMed ID: 22564540
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer.
    Nilsson J; Skog J; Nordstrand A; Baranov V; Mincheva-Nilsson L; Breakefield XO; Widmark A
    Br J Cancer; 2009 May; 100(10):1603-7. PubMed ID: 19401683
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Expression profile of MAGI2 gene as a novel biomarker in combination with major deregulated genes in prostate cancer.
    Mahdian R; Nodouzi V; Asgari M; Rezaie M; Alizadeh J; Yousefi B; Shahrokh H; Abolhasani M; Nowroozi M
    Mol Biol Rep; 2014 Sep; 41(9):6125-31. PubMed ID: 24985972
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Blood-based and urinary prostate cancer biomarkers: a review and comparison of novel biomarkers for detection and treatment decisions.
    Hendriks RJ; van Oort IM; Schalken JA
    Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):12-19. PubMed ID: 27922627
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of ERG and SPINK1 by Immunohistochemical Staining and Clinicopathological Outcomes in a Multi-Institutional Radical Prostatectomy Cohort of 1067 Patients.
    Brooks JD; Wei W; Hawley S; Auman H; Newcomb L; Boyer H; Fazli L; Simko J; Hurtado-Coll A; Troyer DA; Carroll PR; Gleave M; Lance R; Lin DW; Nelson PS; Thompson IM; True LD; Feng Z; McKenney JK
    PLoS One; 2015; 10(7):e0132343. PubMed ID: 26172920
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Zinc α2-glycoprotein as a potential novel urine biomarker for the early diagnosis of prostate cancer.
    Katafigiotis I; Tyritzis SI; Stravodimos KG; Alamanis C; Pavlakis K; Vlahou A; Makridakis M; Katafigioti A; Garbis SD; Constantinides CA
    BJU Int; 2012 Dec; 110(11 Pt B):E688-93. PubMed ID: 23020913
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Utility of PCA3 in patients undergoing repeat biopsy for prostate cancer.
    Wu AK; Reese AC; Cooperberg MR; Sadetsky N; Shinohara K
    Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):100-5. PubMed ID: 22042252
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Novel Biomarker Signature That May Predict Aggressive Disease in African American Men With Prostate Cancer.
    Yamoah K; Johnson MH; Choeurng V; Faisal FA; Yousefi K; Haddad Z; Ross AE; Alshalafa M; Den R; Lal P; Feldman M; Dicker AP; Klein EA; Davicioni E; Rebbeck TR; Schaeffer EM
    J Clin Oncol; 2015 Sep; 33(25):2789-96. PubMed ID: 26195723
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.